Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 7,751 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $70.48, for a total transaction of $546,290.48. Following the completion of the transaction, the director directly owned 1,032,504 shares of the company’s stock, valued at approximately $72,770,881.92. This trade represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The shares were sold at an average price of $70.78, for a total transaction of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The shares were sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA traded up $0.01 during mid-day trading on Monday, reaching $70.24. 674,327 shares of the company were exchanged, compared to its average volume of 499,774. The company’s 50-day simple moving average is $65.53 and its 200-day simple moving average is $66.03. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock has a market capitalization of $2.06 billion, a P/E ratio of -40.37 and a beta of 1.12. Establishment Labs Holdings Inc. has a twelve month low of $32.25 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. Establishment Labs’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.19) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs during the 1st quarter worth approximately $209,000. Patriot Financial Group Insurance Agency LLC grew its holdings in Establishment Labs by 20.4% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 5,450 shares of the company’s stock worth $309,000 after acquiring an additional 925 shares during the last quarter. Cannon Global Investment Management LLC bought a new stake in shares of Establishment Labs in the 1st quarter valued at $738,000. Brian Low Financial Group LLC increased its position in shares of Establishment Labs by 10.2% during the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock worth $261,000 after buying an additional 424 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Establishment Labs by 134.3% during the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock worth $2,154,000 after buying an additional 21,742 shares during the period. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ESTA. BTIG Research restated a “buy” rating and set a $88.00 target price on shares of Establishment Labs in a research note on Wednesday, April 29th. Needham & Company LLC lifted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Mizuho lifted their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.